Jim Cramer Says "I Should Have Pulled the Trigger on Regeneron"

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer looked at. When a caller inquired about the stock, Cramer said:

Oh man, you know what? I should have pulled the trigger on Regeneron when I sat down with them at the JPMorgan conference. I realized that the Charitable Trust should have owned it. It would’ve a much better, really much better drug stock than the others that we have, with the exception of Eli Lilly.

Stock market data. Photo by Photo by Alesia Kozik

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. During the December 1, 2025, episode, a caller highlighted that the stock is up significantly from its summer 2025 lows and asked Cramer if it can continue its momentum. In response, the Mad Money host stated:

Yes, down 30 today… Well, it’s a $750 stock. Now, let me just tell you something. Regeneron’s move has been quiet, but Len Schleifer has been telling me, stay focused on what they’re doing. They’re doing a lot of good stuff. I lost sight of it. I shouldn’t have. This one and Amgen bother me. They happened without me, and that was my bad, and I’m glad you brought it to our attention.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.